Résultats financiers

Initiation of multi-cohort IPH4102 Phase II clinical trial (TELLOMAK) Sézary Syndrome cohort designed to be pivotal; preclinical data supports evaluating larger subsets of patients with T-cell...

Cash, cash equivalents and financial assets of the Company amounted to €237.1 million* Initiation of cohort expansion study of monalizumab and cetuximab to evaluate triple combination with an anti-PD...

Cash, cash equivalents and financial assets* amounted to €202.7m (million euros) as of December 31, 2018 (€176.6m in 2017) Revenue and other income amounted to €94.0m (€36.2m in 2017) Operating...

Acceleration of becoming a fully integrated oncology-focused biotech company through a recent landmark deal with AstraZeneca Expansion of oncology development collaboration with AstraZeneca validates...

Preliminary anti-tumor activity for lead asset, monalizumab, in combination with cetuximab in advanced head and neck cancer and durvalumab in microsatellite-stable colorectal cancer presented at...

Cash, cash equivalents and financial assets of the Company amounted to €153.8 million* Significant momentum across the portfolio, with good progress on the joint monalizumab program with AstraZeneca...

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 29, 2018, at 10:00 am in its headquarters, 117 avenue de Luminy...

Cash, cash equivalents and financial assets* amounted to €176.6m (million euros) as of December 31, 2017 Revenue and other income amounted to €44.0m (€65.7m in 2016, including a €13.8m milestone...

Cash, cash equivalents and financial assets amounting to €195.7 million Robust cash position allows for further investment in portfolio of proprietary immuno-oncology programs Innate Pharma continues...

Cash, cash equivalents and financial assets* for the Company amounted to €204.1m (million euros) as of June 30, 2017 Significant clinical progress within the period: Dose-escalation data of the...